Forty Seven - About the company
Forty Seven is an acquired company based in Palo Alto (United States), founded in 2015. It operates as a Developer of therapies for the treatment of a wide range of diseases. Forty Seven has raised $150M in funding from investors like Lightspeed Venture Partners, Sutter Hill Ventures and Wellington, with last known valuation of $*****. The company has 3386 active competitors, including 1137 funded and 786 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of therapies for the treatment of a wide range of diseases. Its lead program Hu5F9-G4 is a monoclonal antibody against the CD47 receptor. CD47 is a molecule that is overexpressed on the surface of the majority of tumors and transmits a “don’t eat me” signal, enabling cancer cells to evade phagocytosis by macrophages. Also, it is developing drugs for Viral Diseases, Inflammatory Diseases, and Oncology.
- Website
- fortyseveninc.com
- Social
- Registered Address
- Foster City, California
Key Metrics
Founded Year
2015
Location
Palo Alto, United States
Stage
Acquired
Total Funding
$150M in 4 rounds
Latest Funding Round
Last Known Valuation
$***** as on Jun 01, 2018
Investors
Ranked
622nd among 3386 active competitors
Annual Revenue
$10M - $50M as on Dec 31, 2019
Employee Count
7,128 as on Sep 30, 2018
Similar Companies
Exit Details
Acquired by Gilead (Mar 02, 2020)
Legal entities associated with Forty Seven
Forty Seven is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Forty Seven, Inc. CIN: 1667633 , United States, Active | Oct 13, 2014 | $10M - $50M (As on Dec 31, 2019) | - | - |
Gilead Sciences, Inc. CIN: 943047598 , United States, Active | Jun 22, 1987 | - | 11304 (As on Dec 31, 2023) | - |
Forty Seven's acquisition details
Click here to take a look at Forty Seven's acquisition in detail
Sign up to download Forty Seven's company profile
Forty Seven's funding and investors
Forty Seven has raised a total funding of $150M over 4 rounds. Its first funding round was on Feb 24, 2016. Its latest funding round was a Post IPO round on Aug 06, 2019 for $*****. 1 investor participated in its latest round. Forty Seven has 9 institutional investors.
Here is the list of recent funding rounds of Forty Seven:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Aug 06, 2019 | 6748013 | Post IPO | 6896832 | 3161291 | 8591591 | 7762372 |
Dec 06, 2017 | 8975643 | Grant (prize money) | 5865648 | 1154955 | 4639360 | |
Oct 17, 2017 | 2718791 | Series B | 3191431 | 9093234 |
Access funding benchmarks and valuations. Sign up today!View details of Forty Seven's funding rounds and investors
Forty Seven's founders and board of directors
Founder? Claim ProfileForty Seven's employee count trend
Forty Seven has 7,128 employees as of Sep 18. The total employee count is 10.0% more than what it was in Sep 17. Here is Forty Seven's employee count trend over the years:
Uncover Forty Seven's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Forty Seven's Competitors and alternates
Top competitors of Forty Seven include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Forty Seven, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
622nd | Forty Seven 2015, Palo Alto (United States), Acquired | Developer of therapies for the treatment of a wide range of diseases | $150M | 55/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Forty Seven's competitors? Click here to see the top ones
Forty Seven's Investments and acquisitions
Forty Seven has made no investments or acquisitions yet.
Reports related to Forty Seven
Here is the latest report on Forty Seven's sector:
News related to Forty Seven
Filter this list•
•
Paytm Cloud Technologies to enter Brazil’s fintech market with $1M stake in Dinie parentYourStory•Feb 03, 2025•Paytm, Dinie, Enjoy Seven Technology, Razorpay and 6 others
•
•
Lightspeed China Partners Completes Fundraising of $7BPandaily•Jul 15, 2022•Lightspeed Venture Partners, FTX, Forty Seven, Epic Games and 12 others
•
•
ReCode Therapeutics Strengthens Leadership Team With New AppointmentsBusiness Wire•Sep 09, 2020•ReCode Therapeutics, Forty Seven
•
Viracta Announces the Appointment of Mark A. McCamish, MD, PhD as Strategic AdvisorPR Newswire•Jul 20, 2020•Viracta, Forty Seven
•
iTeos Therapeutics Appoints Ann D. Rhoads to Board of DirectorsGlobeNewswire•Jun 01, 2020•iTeos Therapeutics, Forty Seven
•
•
WeissLaw LLP Reminds HXL, FSTV, MINI, and MEET Shareholders About Its Ongoing InvestigationsGlobeNewswire•Mar 12, 2020•Weisslawllp, Woodward, Forty Seven, Mobile Mini Solutions and 1 other
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Forty Seven
Explore our recently published companies
- MTI Education - Russia based, Unfunded company
- Big Tree Entertainment - Mumbai based, 1999 founded, Series D company
- Das Pendawala Foods Pvt - 2009 founded, Unfunded company
- Tsoft IT - Bangladesh based, 2015 founded, Unfunded company
- Linde Homecare - France based, Unfunded company
- John M Orr - Unfunded company
